Evaxion A (EVAX) Research & Development (2020 - 2026)
Evaxion A's (EVAX) quarterly Research & Development came in at -$2.3 million in Q1 2026, down 6.59% YoY from -$2.5 million in Q1 2025, and up 10.2% on a QoQ basis from -$2.6 million in Q4 2025.
Evaxion A (EVAX) Research & Development (2020 - 2026) Analysis & Trends
Evaxion A (EVAX) has 7 years of Research & Development data on file, last reported at -$2.3 million in Q1 2026.
- Quarterly Research & Development fell 6.59% year-over-year to -$2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.1 million (down 3.45% YoY) and the FY2025 annual result came in at -$10.0 million, up 4.61% from the prior year.
- Research & Development climbed to -$2.3 million in Q1 2026, from -$2.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $4.8 million in Q1 2022 to a low of -$4.1 million in Q4 2022.
- A 5-year average of -$1.5 million and a median of -$2.6 million in 2025 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 43.58% in 2023, down 180.18% in 2023.
- Tracing EVAX's Research & Development over 5 years: stood at -$4.1 million in 2022, then soared by 43.58% to -$2.3 million in 2023, then increased by 1.87% to -$2.3 million in 2024, then slipped by 13.48% to -$2.6 million in 2025, then grew by 10.2% to -$2.3 million in 2026.
- The last three Research & Development figures came in at -$2.3 million (Q1 2026), -$2.6 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Evaxion A | 26.86 Mn | 26.86 Mn | - | -2.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.30 Mn |
| Dec 31, 2025 | -2.56 Mn |
| Sep 30, 2025 | -3.09 Mn |
| Jun 30, 2025 | -2.17 Mn |
| Mar 31, 2025 | -2.16 Mn |
| Dec 31, 2024 | -2.26 Mn |
| Sep 30, 2024 | -2.61 Mn |
| Jun 30, 2024 | -2.75 Mn |
| Mar 31, 2024 | -2.84 Mn |
| Dec 31, 2023 | -2.30 Mn |
| Sep 30, 2023 | -2.83 Mn |
| Jun 30, 2023 | -2.94 Mn |
| Mar 31, 2023 | -3.85 Mn |
| Dec 31, 2022 | -4.07 Mn |
| Sep 30, 2022 | 4.07 Mn |
| Jun 30, 2022 | 4.11 Mn |
| Mar 31, 2022 | 4.80 Mn |
| Dec 31, 2021 | 6.15 Mn |
| Sep 30, 2021 | 13.43 Mn |
| Jun 30, 2021 | 9.00 Mn |